Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer

New Migraine Drugs No Better Than Cheap Painkillers: Big Study

Migraine drugs can represent big money for pharmaceutical firms, as shown when Pfizer acquired Biohaven -- which developed rimegepant -- for more than $10 billion in 2022.

Latin Times

Will the XEC COVID subvariant bring a fall wave of infections? What to know about symptoms and spread

The U.S. is coming down from its biggest COVID summer surge yet as a new subvariant emerges—but new vaccines are here, too.

Fortune

Covid conspiracy theorist convicted of terrorism after Telegram calls for vaccine violence

Patrick Ruane, 55, from Paddington, west London, weaponised social media app Telegram to encourage attacks

Evening Standard

From analysis to the latest developments in health,
read the most diverse news in one place.

New COVID vaccines may be coming to Australia. Here’s what to know about the JN.1 shots

COVID vaccines have unquestionably made a huge difference during this pandemic. For example, it’s estimated COVID shots have saved more than 1.4 million lives in the World Health Organization’s (WHO) European region alone since their introduction in December 2020.

The Conversation

A mural honoring scientists hung in Pfizer's NYC lobby for 60 years. Now it's up for grabs

A New York City mural honoring ancient and modern figures in medicine could end up in pieces if it can’t find a new patron soon

The Independent UK

You Can Stop Looking, Here's the Perfect Stock for the Current Market

While technology stocks continue to struggle, stocks in the lucrative over-the-counter healthcare products sector are thriving. One prominent such name is Haleon. Its stock has jumped more than 22% over the past three months, as sales and profits in its nine large-scale multinational, high-margin 'power brands' continue to hold leading…

Barchart

Is Pfizer Stock Underperforming the Dow?

Although Pfizer underperformed the Dow Jones this year, analysts are moderately bullish on the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Vaxcyte Catapults As It Looks To Take On Pfizer, Merck In A Massive Market

Vaxcyte shares rocketed Tuesday after the biotech company delivered "stunning" test results for its pneumococcal vaccine.

Investors Business Daily

Why IBD 50's Alnylam Just Reversed Its 50% Gain — And BridgeBio Surged

Alnylam stock tumbled Friday after the company's Pfizer-rivaling heart disease treatment lagged expectations in a lengthy study.

Investors Business Daily

COVID-19, flu and RSV shots − an epidemiologist explains why all three matter this fall

The Food and Drug Administration approved and granted emergency use authorization on Aug. 22, 2024, for the newest, updated version of the COVID-19 vaccine. The Centers for Disease Control and Prevention quickly endorsed the new shot to protect against severe illness.

The Conversation

The 10 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

Investors Business Daily

New COVID vaccines are here. What to know about 2024–25 shots as summer surge continues

Citing skyrocketing COVID spread, the FDA announced in late August that it had approved Pfizer’s Comirnaty and Moderna’s Spikevax vaccines early.

Fortune

A new Covid vaccine is available. Here’s why some people might not want it right away

Updated Covid vaccines were approved by the FDA earlier this month

The Independent UK

FDA Approves Updated Covid-19 Vaccines From Moderna And Pfizer

FDA approves updated Covid-19 vaccines from Moderna and Pfizer/BioNTech to enhance protection against current variants and combat rising cases.

Top News

Pfizer's Dividend Yield Surpasses 6% Mark, Attracting Investors

Learn about the role of dividends in stock market returns and the significance of sustainable yields, using Pfizer as an example.

Investors Business Daily

Pfizer Slides Toward Sell Zone After BioNTech-Tied Covid/Flu Shot Misses Its Mark

Pfizer stock toppled Friday after the pharma giant reported mixed results for its BioNTech-partnered combination flu and Covid vaccine.

The Independent UK

Pfizer CEO on moving beyond COVID vaccines to become a leader in cancer and obesity treatments

Pfizer's CEO Albert Bourla is trying to reposition the global pharmaceutical giant for a post-pandemic world

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

Food and Drug Administration

328 stories

GSK

316 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.